You are here

Positive Top Line Results Reported for Phase 2 Trial Evaluating Darusentan

DENVER, Aug. 18 /PRNewswire-FirstCall/ -- Myogen, Inc. (NASDAQ:MYOG) today announced positive top line results of its Phase 2b trial evaluating darusentan in resistant hypertension. Results of the trial demonstrated that 300 mg of darusentan dosed once daily provided statistically significant, placebo-corrected reductions of 11.6 mmHg (p=0.02) in systolic blood pressure and 7.0 mmHg (p "We are highly encouraged by the results of this trial," said J. William Freytag, President and Chief Executive Officer of Myogen. "There are millions of hypertensive patients in the United States currently being treated with three or more antihypertensive therapies. A significant percentage of these patients are not at goal blood pressures and are at increased risk of cardiovascular events. As an endothelin receptor antagonist, darusentan affects blood pressure through a mechanism of action different than those of currently approved antihypertensive drugs. The results of this trial indicate darusentan could provide additional blood pressure lowering benefit in this patient population. This positive outcome advances our mission to improve the quality of life of patients who suffer from debilitating cardiovascular disorders."

"These results are particularly gratifying considering that these patients were already on full doses of three antihypertensive medications including a diuretic," commented Michael J. Gerber, M.D., Senior Vice President, Clinical Development and Regulatory Affairs. "To the best of our knowledge, no other antihypertensive agent has ever been shown to have efficacy in this setting. This outcome supports our optimism that darusentan has the potential to improve the treatment options available to physicians trying to manage this complex disorder. We look forward to initiating a Phase 3 program to evaluate darusentan in a larger, international patient population."

About DAR-201
The primary objective of this Phase 2b randomized, double-blind, placebo-controlled trial was to determine if darusentan is effective in reducing systolic blood pressure in patients with resistant hypertension. Patients were eligible for enrollment in this trial if they had a systolic blood pressure greater than or equal to 140 mmHg and a diastolic blood pressure greater than 90 mmHg despite treatment with full doses of three anti-hypertensive medications, one of which was a diuretic, and no other compelling conditions. For patients with diabetes and chronic renal disease, systolic and diastolic blood pressures inclusion criteria were more stringent, namely a systolic blood pressure greater than 130 mmHg and a diastolic blood pressure greater than 80 mmHg. A total of 115 patients were randomized to darusentan or placebo at approximately 30 investigative sites in the U.S. Patients underwent forced titration every two weeks through 10, 50, 100 and 150 mg of darusentan or placebo until the target dose of 300 mg once daily was achieved. The treatment period was ten weeks followed by a two week drug withdrawal period.

About Resistant Hypertension
Hypertension affects approximately 50 million individuals in the United States and approximately one billion worldwide. Despite the availability and use of several classes of drugs (diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, central alpha receptor agonists, peripheral alpha antagonists and vasodilators) to treat hypertension, a significant percentage of these patients (20-30% according to recently published data) fail to achieve blood pressures within the recommended range.

The "Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure" (JNC7) defines resistant hypertension as "the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic." According to JNC7, a systolic blood pressure of less than 140 mmHg and a diastolic blood pressure of less than 90 mmHg are recommended for patients with hypertension and no other serious conditions. For patients with diabetes and chronic renal disease, target systolic and diastolic blood pressures are more stringent -- a systolic blood pressure goal of less than 130 mmHg and a diastolic blood pressure goal of less than 80 mmHg.

About Darusentan
Darusentan is a type-A selective endothelin receptor antagonist (ERA) and potent inhibitor of endothelin-induced vasoconstriction. Endothelin is a small peptide hormone that is believed to play a critical role in the control of blood flow and cell growth. Elevated endothelin blood levels are associated with several cardiovascular disease conditions, including hypertension, pulmonary arterial hypertension, chronic renal disease, coronary artery disease and chronic heart failure. Therefore, the Company believes that agents that block the detrimental effects of endothelin may provide significant benefits in the treatment of these conditions. Darusentan demonstrates high potency, high bioavailability and a half-life we believe is suitable for once daily dosing. In a prior clinical study in patients with moderate essential hypertension, darusentan demonstrated statistically significant and clinically meaningful dose-dependent reductions in systolic and diastolic blood pressures.

Source: Myogen, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress